



Department of Health Care Finance
441 Fourth Street NW
Main Street Conference Room 1028 (10th Floor)
Washington DC, 20001



**PHARMACY & THERAPEUTICS
COMMITTEE MEETING
Thursday, March 5th, 2020
Time: 2:30 PM – 5:30 PM**

- 1) Call to Order Charlene Fairfax, RPh
- 2) Minutes of Previous Meeting Charlene Fairfax, RPh
- 3) Comments from Interested Parties* Gidey Amare, RPh, MS
- 4) Clinical Drug Class Reviews Zakia Al-Amin, PharmD, BCACP, RPh
Ronald E. Kavanagh, BSP Pharm, PharmD, PhD, RPh

Androgenic Agents	Hyperparathyroidism Agents (<i>Tentative</i>)
Antibiotics, Vaginal	Hypoglycemics, Incretin Mimetics/Enhancers
Antiemetics/Antivertigo Agents	Hypoglycemics, Insulins
Antihyperuricemics	Hypoglycemics, Meglitinides
Bladder Relaxants	Hypoglycemics, Metformins
Bone Resorption and Suppression Agents	Hypoglycemics, SGLT2 Inhibitors
BPH Agents	Hypoglycemics, Thiazolidinediones
Colony Stimulating Factors	Pancreatic Enzymes
Erythropoiesis Stimulating Agents	Phosphate Binders
GI Motility, Chronic; Irritable Bowel	Progestins For Cachexia
Growth Hormone	Proton Pump Inhibitors
H. Pylori Agents	Ulcerative Colitis Agents
Histamine-2-Receptor Antagonists	Vaginal Estrogen Preparations

- 5) Executive Session (Committee Only)** Charlene Fairfax, RPh
MMA Representatives
- 6) Final Recommendations of Preferred Drugs*** MMA Representatives
- 7) Announcement of Next Scheduled P&T Committee Meeting Charlene Fairfax, RPh

Thursday, June 4th, 2020
- 8) Final Comments and Adjournment Charlene Fairfax, RPh

***Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only **Closed Session ***Open Session**